Compare Incyte Corporation (INCY) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Snap Inc — how do they compare? Incyte Corporation trades at $121.25 (market cap $24.54B), while Snap Inc trades at $5.28 (market cap $9.32B). The key difference: Incyte Corporation is far larger — about 2.6× Snap Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SNAP | |
|---|---|---|
Market Cap | $24.54B | $9.32B |
Sector | Health | Media |
52-Week High | $129.93 | $9.09 |
52-Week Low | $81.61 | $3.93 |
Enterprise Value | $20.04B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Snap Inc. (SNAP) trades at $5.34, up 0.19% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth of 19% year-over-year to $1.60 billion and a narrowing net loss, beating analyst expectations. Operating cash flow strengthened to $656 million in 2025, while the stock trades below the consensus price target of $7.02 with 38% of analysts rating it a buy.
The outlook suggests potential upside from continued advertising revenue growth and cost discipline, but risks include persistent net losses, high debt levels, and competitive pressures in social media. Investor sentiment is cautiously optimistic amid earnings beats and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
